October 9, 2018

Cerevance Appoints Ted Hibben as Chief Business Officer

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Boston, MA – October 9, 2018 – Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced that it has appointed Ted Hibben as Chief Business Officer. A twenty-year biotechnology industry veteran, Mr. Hibben has formed over $2 billion in platform and product-based R&D collaborations.

Prior to joining Cerevance, Mr. Hibben served as Chief Business Officer at Catabasis where he led partnering activities. Before Catabasis, he was Senior Vice President of Ensemble Therapeutics where he formed multi-year, multi-target discovery and development-stage collaborations. His experience also includes serving as Chief Business Officer at the RNAi product platform company, Cequent Pharmaceuticals, and as Vice President of Business Development and Alliance Management at the immunomodulatory company, Coley Pharmaceutical Group, where he orchestrated nine development alliances.

“We’re looking forward to having Ted’s leadership in identifying, structuring and negotiating creative partnerships with pharmaceutical and biotechnology companies that will provide critical validation of our technology platform and execution ability,” said Brad Margus, CEO of Cerevance. “As our discovery platform has begun yielding novel targets and our lead compounds advance through clinical development, his strategic partnering expertise will be critical.”

Mr. Hibben earned his M.B.A. from Harvard University and his A.B. from Dartmouth College. Throughout his career, he has been involved with external and in-house programs ranging from discovery through Phase 3 in therapeutic areas spanning a full range of modalities including biologics, small molecules and vaccines.

“Patients with neurological and psychiatric diseases are desperate for better treatments, and our industry urgently needs new CNS targets to pursue,” said Mr. Hibben. “I’m looking forward to working with the Cerevance team to form strategic partnerships that will harness the company’s unique capability to solve these problems.”

About Cerevance

Cerevance is a private pharmaceutical company focused on central nervous system diseases. The company’s strengths include its powerful NETSseq target discovery platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. Its scientists believe that they are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders. For additional information, please visit www.cerevance.com.



Robert Middlebrook, +1-408-220-5722